

## **Pharmacy Drug Policy Checklist**

POLICY NAME Inbrija (levodopa inhalation powder) POLICY # 2695P

## Criteria

Coverage Criteria	
	1.1 Diagnosis of advanced Parkinson's disease
	1.2 Age 18 years of age
	1.3 Ordered by or in consultation with a neurologist (doctor of the central nervous system)
	<ul> <li>1.4 Documentation that member is experiencing "off" episodes (return of Parkinson's symptoms) while receiving a carbidopa/levodopa regiment where:</li> <li>Attempts have been made to adjust the carbidopa/levodopa's dose and/or formulation in order to manage symptoms without success</li> <li>Member will continue receiving with carbidopa/levodopa in combination with Inbrija</li> </ul>
	<ul> <li>1.5 Member has had previous inadequate responses, intolerance, or contraindication to at least two different classes of medications for the treatment of Parkinson's disease</li> <li>Monoamine oxidase type B inhibitors</li> <li>Dopamine agonists</li> <li>Catechol-O-methyl transferase inhibitors</li> </ul>